HOLX
HealthcareHologic, Inc. · Medical - Instruments & Supplies · $17B
What is Hologic, Inc.?
Hologic is a large-cap healthcare company focused exclusively on women's health — developing diagnostics, medical imaging, and surgical products used by clinicians across the United States and internationally.
Hologic generates revenue across four business segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. Its diagnostics arm sells molecular assay platforms and infectious disease tests. The Breast Health segment provides mammography systems and biopsy tools. GYN Surgical offers devices for treating abnormal uterine bleeding and fibroid removal. This diversified model across clinical settings gives the company multiple revenue streams within a single therapeutic focus.
Founded in 1990 and headquartered in Marlborough, Massachusetts, Hologic has built a portfolio centered on early detection and minimally invasive treatment.
- Aptima molecular diagnostic assays for infectious disease detection
- 2D and 3D digital mammography and breast biopsy systems
- NovaSure Endometrial Ablation System for uterine bleeding
- MyoSure Hysteroscopic Tissue Removal System for fibroids and polyps
- ThinPrep System for cytology and cervical cancer screening
Is HOLX a Good Stock to Buy?
UQS Score rates HOLX as Good overall, reflecting a balanced but uneven profile across its five quality pillars.
The Risk pillar and Valuation pillar both register as Good, suggesting the stock carries manageable financial risk and does not appear stretched relative to its fundamentals. That combination can appeal to investors who prioritize capital preservation alongside reasonable entry pricing.
The Growth pillar rates as Weak, indicating that near-term revenue expansion may lag sector peers — a meaningful consideration for growth-oriented investors. Quality and Moat both sit at Neutral, pointing to a business that is competent but not yet differentiated enough to score at the top of its sector.
See the exact pillar breakdown and full financial metrics by signing up for a UQS Pro account. Sign up free →
Past performance does not guarantee future results. UQS Score is based on fundamental data and is not a buy/sell recommendation.
Does HOLX pay dividends?
No — Hologic, Inc. does not currently pay a dividend.
Hologic does not currently pay a dividend. For a company operating in medical devices and diagnostics, this is common — available capital tends to be directed toward research and development, product pipeline expansion, and strategic acquisitions rather than shareholder distributions. Investors seeking income from this sector may need to look elsewhere, while those focused on reinvestment may find the approach consistent with long-term business building.
When does HOLX report earnings?
Hologic reports earnings on a quarterly cadence, consistent with standard practice for US-listed equities.
The company's recent results reflect the post-pandemic normalization of its diagnostics segment, which saw elevated demand during the COVID-19 period. Underlying women's health franchises in breast imaging and GYN surgical have continued to contribute to the revenue base, though overall growth has moderated.
For the most recent quarter's results and guidance, visit Hologic's official investor relations page.
HOLX Price History
+20.5% over 5Y
Monthly close, adjusted for stock splits and dividend reinvestment.
What if I invested in Hologic, Inc.?
Based on Hologic, Inc.'s historical closing prices, adjusted for stock splits and dividend reinvestment. Past performance does not guarantee future results. This is for informational purposes only and is not financial advice.
HOLX Long-term Outlook
Hologic's fundamental outlook is shaped by a Weak Growth pillar alongside Good Risk and Valuation ratings. The near-term trajectory suggests modest expansion rather than acceleration, as the diagnostics segment laps a period of outsized COVID-related revenue. The core women's health portfolio provides a relatively stable base, but meaningful top-line re-acceleration would likely require new product cycles or market share gains in existing segments.
Growth drivers
- Expansion of molecular diagnostics beyond COVID into broader infectious disease testing
- Adoption of 3D mammography systems in underpenetrated international markets
- Procedural volume recovery in GYN surgical following post-pandemic normalization
Key risks
- Sustained revenue headwind as COVID-era diagnostics demand continues to normalize
- Competitive pressure in breast imaging and molecular diagnostics from larger device makers
- Valuation sensitivity if growth does not recover to justify current market pricing
HOLX vs Peers
Hologic competes across diagnostics and medical devices, where several specialized healthcare companies address overlapping clinical markets.
Straumann focuses on dental implants and oral reconstruction rather than women's health, making it a peer in the broader medical device space but not a direct clinical competitor.
West Pharmaceutical specializes in drug delivery components and packaging systems, serving the pharmaceutical supply chain rather than diagnostic or surgical end markets.
Cooper Companies operates in both contact lens solutions and fertility-focused medical devices, sharing Hologic's women's health orientation but competing in different product categories.
Frequently Asked Questions
What does Hologic do?
Hologic develops and sells diagnostics, medical imaging systems, and surgical products focused entirely on women's health. Its four business segments — Diagnostics, Breast Health, GYN Surgical, and Skeletal Health — serve hospitals, clinics, and screening programs across the US and internationally.
Does HOLX pay dividends?
No, Hologic does not currently pay a dividend. The company reinvests available capital into its product pipeline, research, and acquisitions. Investors seeking regular income distributions would need to consider other healthcare names.
When does HOLX report earnings?
Hologic reports on a quarterly cadence, as is standard for US-listed companies. Specific dates are not covered by our data source — check Hologic's investor relations page for the current reporting schedule.
Is HOLX a good stock to buy?
UQS Score rates HOLX as Good overall. The Risk and Valuation pillars are both rated Good, which may appeal to investors focused on downside management. However, the Weak Growth pillar is a notable consideration. The full pillar breakdown is available to Pro members.
Is HOLX overvalued?
The UQS Valuation pillar for HOLX is rated Good, suggesting the stock does not appear significantly stretched relative to its fundamentals at the time of scoring. Valuation assessments can shift with earnings revisions and market conditions, so ongoing monitoring matters.
How does HOLX compare to its competitors?
Among the peers tracked by UQS, Hologic's women's health focus is relatively unique. Cooper Companies shares some overlap in women's health devices, while West Pharmaceutical and Straumann operate in distinct niches. Side-by-side UQS pillar comparisons are available on each company's score page.
What is HOLX's market cap bracket?
Hologic is classified as a large-cap company. This places it among the more established and liquid names in the medical devices and diagnostics space, typically associated with greater institutional coverage and lower liquidity risk than smaller peers.
Who founded Hologic?
Hologic was founded in 1990. Detailed founding history, including the names of its original founders, is widely available through public company records and Hologic's own corporate history disclosures.
Is HOLX a long-term quality investment?
As a long-term quality indicator, HOLX's Good UQS Score reflects a company with manageable risk and reasonable valuation, but a Weak Growth pillar and Neutral Quality and Moat ratings suggest it has room to strengthen its competitive position before ranking among the sector's top-tier names.
What is the main competitive advantage of Hologic?
Hologic's primary advantage is its singular focus on women's health, which has allowed it to build deep clinical relationships and a broad product portfolio spanning screening, diagnosis, and treatment. Its Moat pillar currently rates as Neutral, indicating this advantage is present but not yet exceptional relative to peers.
What sector does HOLX belong to?
Hologic operates in the Healthcare sector, specifically within medical devices and diagnostics. Its products serve clinical workflows in women's health, including mammography screening programs, molecular diagnostic labs, and minimally invasive surgical suites.
Is HOLX a growth stock or value stock?
Based on UQS pillar labels, HOLX leans toward value characteristics — the Valuation pillar is Good while the Growth pillar is Weak. This profile may suit investors looking for reasonably priced healthcare exposure rather than high-growth momentum.
Unlock Full HOLX Analysis
Sign in to unlock the detailed analysis behind the UQS Score.
- ✓View the complete five-pillar UQS Score breakdown
- ✓Access detailed financial metrics behind each pillar rating
- ✓Compare HOLX side-by-side with sector peers
- ✓Track score changes as new earnings data arrives
- ✓Filter top-rated healthcare stocks by pillar strength
- ✓Get the full analyst-grade view in one place
Pro Analysis
HOLX — Score History
| Date | UQS | Quality | Moat | Growth | Risk | Value | Change |
|---|---|---|---|---|---|---|---|
| May 21, 2026 | 52.7 | 56.8 | 42.0 | 29.8 | 77.8 | 69.0 | -0.3 |
| Apr 30, 2026 | 53.0 | 56.8 | 42.0 | 29.8 | 77.8 | 71.1 | +0.1 |
| Apr 25, 2026 | 52.9 | 56.8 | 42.0 | 29.8 | 77.8 | 70.6 | 0.0 |
| Apr 23, 2026 | 52.9 | 56.8 | 42.0 | 29.8 | 77.8 | 70.8 | -0.2 |
| Apr 18, 2026 | 53.1 | 56.8 | 42.0 | 29.8 | 77.8 | 71.6 | -1.4 |
| Apr 12, 2026 | 54.5 | 56.8 | 42.0 | 29.8 | 77.8 | 80.9 | 0.0 |
| Apr 2, 2026 | 54.5 | 56.8 | 42.0 | 29.8 | 77.8 | 81.1 | — |
HOLX — Pillar Breakdown
Quality
— 56.8/100 (25%)Hologic, Inc. shows solid profitability with healthy returns on capital and reasonable margins.
How effectively capital is deployed to generate returns.
Profitability relative to shareholders' equity.
Ability to convert revenue into operating profit.
Bottom-line profit as a share of revenue.
Asset productivity — how much gross profit each dollar of assets generates.
Free cash flow relative to market value.
Growth
— 29.8/100 (20%)Hologic, Inc. faces growth headwinds with declining or stagnant revenue trends.
Revenue trajectory over the last twelve months.
Compound annual revenue growth rate over 3 years.
Year-over-year earnings per share growth.
Analyst consensus for future revenue growth.
Analyst consensus for future earnings growth.
Risk
— 77.8/100 (15%)Hologic, Inc. carries minimal financial risk with conservative leverage and strong solvency.
Debt levels relative to earnings capacity.
Total debt relative to shareholder equity.
Short-term liquidity — ability to pay near-term obligations.
Earnings capacity relative to interest payments.
Valuation
— 69.0/100 (15%)Hologic, Inc. trades at a reasonable valuation with decent earnings yield and FCF multiples.
Inverse of forward P/E — higher yield means cheaper stock.
How many years of FCF the market cap represents.
P/E relative to earnings growth — lower is more attractive.
Enterprise value multiple relative to sector median.
Moat
— 42/100 (25%)Hologic, Inc. possesses some competitive advantages but faces meaningful competition. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for HOLX.
Score Composition
Financial Data
More Stock Analysis
How is the HOLX UQS Score Calculated?
The UQS (Unified Quality Score) for Hologic, Inc. is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.
Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.
Moat (25%) assesses Hologic, Inc.'s competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.
Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.
Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.
Valuation (15%) measures whether Hologic, Inc. is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.
Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.